These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7585035)

  • 21. Selective phosphodiesterase-3 inhibitor cilostazol ameliorates experimental autoimmune encephalomyelitis.
    Kureshiro J; Miyamoto K; Tanaka N; Kusunoki S
    Neuroreport; 2009 May; 20(7):718-22. PubMed ID: 19402218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and biochemical effects of the selective phosphodiesterase inhibitor rolipram in depressed inpatients controlled by determination of plasma level.
    Laux G; Becker T; Kühne G; Lesch KP; Riederer P; Beckmann H
    Pharmacopsychiatry; 1988 Nov; 21(6):378-9. PubMed ID: 3244773
    [No Abstract]   [Full Text] [Related]  

  • 23. The specific type IV phosphodiesterase inhibitor rolipram combined with adenosine reduces tumor necrosis factor-alpha-primed neutrophil oxidative activity.
    Sullivan GW; Carper HT; Mandell GL
    Int J Immunopharmacol; 1995 Oct; 17(10):793-803. PubMed ID: 8707444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
    Kleinman EF; Campbell E; Giordano LA; Cohan VL; Jenkinson TH; Cheng JB; Shirley JT; Pettipher ER; Salter ED; Hibbs TA; DiCapua FM; Bordner J
    J Med Chem; 1998 Jan; 41(3):266-70. PubMed ID: 9464356
    [No Abstract]   [Full Text] [Related]  

  • 25. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages.
    Kambayashi T; Jacob CO; Zhou D; Mazurek N; Fong M; Strassmann G
    J Immunol; 1995 Nov; 155(10):4909-16. PubMed ID: 7594495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential effects of phosphodiesterase type 4-specific inhibition on human autoreactive myelin-specific T cell clones.
    Pette M; Muraro PA; Pette DF; Dinter H; McFarland HF; Martin R
    J Neuroimmunol; 1999 Aug; 98(2):147-56. PubMed ID: 10430048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease.
    Sommer N; Martin R; McFarland HF; Quigley L; Cannella B; Raine CS; Scott DE; Löschmann PA; Racke MK
    J Neuroimmunol; 1997 Oct; 79(1):54-61. PubMed ID: 9357447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protection by a cyclic AMP-specific phosphodiesterase inhibitor, rolipram, and dibutyryl cyclic AMP against Propionibacterium acnes and lipopolysaccharide-induced mouse hepatitis.
    Taguchi I; Oka K; Kitamura K; Sugiura M; Oku A; Matsumoto M
    Inflamm Res; 1999 Jul; 48(7):380-5. PubMed ID: 10450787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of tumour necrosis factor production by adrenal hormones in vivo: insights into the antiinflammatory activity of rolipram.
    Pettipher ER; Labasi JM; Salter ED; Stam EJ; Cheng JB; Griffiths RJ
    Br J Pharmacol; 1996 Apr; 117(7):1530-4. PubMed ID: 8730750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of phosphodiesterase inhibitors on cytokine production by microglia.
    Yoshikawa M; Suzumura A; Tamaru T; Takayanagi T; Sawada M
    Mult Scler; 1999 Apr; 5(2):126-33. PubMed ID: 10335522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of vesnarinone on TNF alpha production in human peripheral blood mononuclear cells and microglia: a preclinical study for the treatment of multiple sclerosis.
    Jiang H; Bielekova B; Okazaki H; Clarence-Smith K; Johnson KP; Bergey G; Martin R; Dhib-Jalbut S
    J Neuroimmunol; 1999 Jun; 97(1-2):134-45. PubMed ID: 10408967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram.
    Ross SE; Williams RO; Mason LJ; Mauri C; Marinova-Mutafchieva L; Malfait AM; Maini RN; Feldmann M
    J Immunol; 1997 Dec; 159(12):6253-9. PubMed ID: 9550429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of thalidomide and pentoxifylline on experimental autoimmune encephalomyelitis (EAE).
    Corrêa JO; Aarestrup BJ; Aarestrup FM
    Exp Neurol; 2010 Nov; 226(1):15-23. PubMed ID: 20406639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Type IV phosphodiesterase inhibitor is effective in prevention and treatment of experimental crescentic glomerulonephritis.
    Tam FW; Smith J; Agarwal S; Karkar AM; Morel D; Thompson EM; Pusey CD
    Nephron; 2000 Jan; 84(1):58-66. PubMed ID: 10644909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation.
    Sekut L; Yarnall D; Stimpson SA; Noel LS; Bateman-Fite R; Clark RL; Brackeen MF; Menius JA; Connolly KM
    Clin Exp Immunol; 1995 Apr; 100(1):126-32. PubMed ID: 7697910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
    Seldon PM; Barnes PJ; Giembycz MA
    Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
    Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
    Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
    Seldon PM; Barnes PJ; Meja K; Giembycz MA
    Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells.
    Semmler J; Wachtel H; Endres S
    Int J Immunopharmacol; 1993 Apr; 15(3):409-13. PubMed ID: 8505151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-alpha and nitric oxide.
    Greten TF; Eigler A; Sinha B; Moeller J; Endres S
    Int J Immunopharmacol; 1995 Jul; 17(7):605-10. PubMed ID: 8586489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.